Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FEBUXOSTAT vs ULORIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Febuxostat is a non-purine selective inhibitor of xanthine oxidase (XO). It inhibits both oxidized and reduced forms of XO, thereby reducing the conversion of hypoxanthine to xanthine and xanthine to uric acid, leading to decreased serum uric acid levels.
ULORIC (febuxostat) is a xanthine oxidase inhibitor that reduces serum uric acid levels by inhibiting the enzyme xanthine oxidase, which catalyzes the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Chronic management of hyperuricemia in patients with gout,Off-label: Prevention of tumor lysis syndrome,Off-label: Management of hyperuricemia in kidney transplant recipients
Chronic management of hyperuricemia in patients with gout,Off-label: Prevention of tumor lysis syndrome (not FDA-approved)
40 mg orally once daily; may increase to 80 mg orally once daily if serum urate goal not achieved after 2 weeks.
40 mg orally once daily; may increase to 80 mg once daily if serum uric acid not at target after 2 weeks.
Terminal elimination half-life: 5-8 hours in healthy subjects; prolonged in renal impairment (e.g., up to 9.6 hours in moderate impairment). Clinical context: dosing interval is once daily, consistent with half-life.
Terminal elimination half-life is approximately 5-8 hours. This short half-life supports once-daily dosing for maintenance of therapeutic urate-lowering effect.
Primarily metabolized by conjugation via UDP-glucuronosyltransferases (UGT1A1, UGT1A3, UGT1A9, and UGT2B7) and oxidation via cytochrome P450 (CYP) enzymes, including CYP1A2, CYP2C8, and CYP2C9, with minor contribution from CYP3A4/5.
Primarily metabolized by UGT1A1, UGT1A3, UGT1A9, and CYP2C8; minor metabolism by CYP1A2, CYP2C9, and CYP2D6. Approximately 22% excreted unchanged in urine.
Renal: 1-3% unchanged; biliary/fecal: ~50% as metabolites (acyl glucuronides, oxidative metabolites); other: ~49% metabolized and eliminated via multiple pathways including biliary and direct intestinal excretion of unchanged drug.
Renal excretion of unchanged drug accounts for approximately 40-45% of the dose. Biliary/fecal excretion eliminates about 50-55% of the dose, primarily as oxidative metabolites.
99% (primarily to albumin; minor binding to alpha-1-acid glycoprotein).
Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 0.7 L/kg (indicating distribution into total body water; not extensively tissue-bound).
Apparent volume of distribution is about 50 L (approximately 0.7 L/kg). This suggests distribution into total body water and some tissue binding.
Oral: at least 49% (absolute bioavailability not established; estimated based on mass balance studies).
Oral bioavailability is approximately 85% (range 60-100%). Tablets are well absorbed, with food having no significant effect on overall absorption.
No dose adjustment required for mild to moderate renal impairment (e GFR 30-89 m L/min). For severe renal impairment (e GFR <30 m L/min), limited data; use with caution, not recommended in dialysis.
No dose adjustment required for mild to moderate renal impairment (GFR 30-89 m L/min). Not recommended for use in patients with severe renal impairment (GFR <30 m L/min) or end-stage renal disease on dialysis due to lack of efficacy data.
Child-Pugh Class A or B: no dose adjustment. Child-Pugh Class C: not recommended (no studies).
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B). Not recommended in severe hepatic impairment (Child-Pugh Class C) due to lack of data.
Not approved for pediatric use; safety and efficacy not established.
Safety and efficacy not established in pediatric patients; no FDA-approved dosing.
No specific dose adjustment required; use with caution due to potential for decreased renal function.
No specific dose adjustment required; clinical studies included patients aged 65 and older with no overall differences in safety or efficacy observed.
Increased risk of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent revascularization in patients with established cardiovascular disease (based on the CARES trial). Febuxostat should be avoided in patients with a history of myocardial infarction or stroke, unless no other therapy is appropriate.
Increased risk of cardiovascular death compared to allopurinol in patients with gout and cardiovascular disease. Febuxostat should be used only in patients who have not responded adequately to allopurinol or have contraindications to allopurinol.
Cardiovascular events (see black box warning); hepatotoxicity (elevated liver enzymes, hepatic failure); gout flares upon initiation (prophylaxis recommended); renal impairment (dose adjustment for severe impairment); hypersensitivity reactions (including Stevens-Johnson syndrome); thyroid function abnormalities (elevated TSH).
Cardiovascular events: Increased risk of cardiovascular death, especially in patients with pre-existing cardiovascular disease.,Gout flare: May increase frequency of gout flares during initiation; prophylaxis with NSAIDs or colchicine recommended.,Liver enzyme elevations: Monitor liver function tests; discontinue if persistent elevation or signs of liver injury.,Thyroid disorders: Can increase TSH levels; monitor thyroid function.,Renal impairment: Dose adjustment not required; limited data in severe renal impairment.,Drug interactions: Use with caution with azathioprine, mercaptopurine, or theophylline; increase risk of toxicity.
Concurrent use with azathioprine, 6-mercaptopurine, or theophylline (due to risk of toxicity); severe renal impairment (Cr Cl <30 m L/min) based on trial data; history of myocardial infarction or stroke (relative contraindication per FDA).
History of hypersensitivity to febuxostat,Concurrent use with azathioprine, mercaptopurine, or theophylline (absolute)
No specific food interactions are reported, but high-purine foods (red meat, organ meats, shellfish) and alcohol may increase serum urate and counteract drug efficacy; advise moderation and limit intake during therapy.
No specific food interactions; however, high-purine foods (e.g., organ meats, anchovies, sardines, scallops, game meats, beer) may counteract efficacy by raising uric acid. Grapefruit juice has no known interaction with febuxostat. Avoid excessive alcohol, especially beer and spirits, as they increase urate levels.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, febuxostat caused developmental toxicity (reduced fetal weight, increased skeletal variations) at maternal toxic doses. First trimester: unknown risk; avoid unless benefits outweigh risks. Second/third trimester: limited data; potential for fetal harm based on animal findings.
Pregnancy Category C: In animal studies, febuxostat caused fetal toxicity (reduced fetal weights, increased incidence of fetal malformations) at doses equivalent to 2-4 times the human exposure. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if potential benefit justifies potential risk to fetus. First trimester: limited data; second and third trimesters: theoretical risk of uric acid reduction impacting fetal growth due to role of uric acid in fetal development.
Excretion in human milk unknown; M/P ratio not determined. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy.
Excretion in human milk unknown; M/P ratio not determined. Because many drugs are excreted in human milk and potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue drug, taking into account importance of drug to mother.
No specific pharmacokinetic data in pregnancy. Due to potential teratogenicity, avoid in pregnancy. If use is unavoidable, no dose adjustment studies exist; use lowest effective dose with caution.
No specific dose adjustments recommended for pregnancy due to lack of pharmacokinetic data. Physiological changes in pregnancy (increased plasma volume, renal blood flow, and glomerular filtration rate) may reduce serum uric acid levels; however, no dose modification studies have been conducted. Use lowest effective dose if treatment necessary.
Febuxostat is a non-purine selective xanthine oxidase inhibitor indicated for chronic management of hyperuricemia in gout. It is contraindicated with concomitant azathioprine, mercaptopurine, or theophylline due to risk of toxicity. Initiate at 40 mg daily; titrate to 80 mg if serum urate not at target after 2 weeks. Monitor for gout flares during initiation; provide prophylactic NSAIDs or colchicine for at least 6 months. Cardiovascular risk: increased risk of cardiovascular death vs allopurinol in patients with history of CV disease; avoid as first-line or in patients with prior MI or stroke. Assess liver function tests at baseline and periodically; discontinue if persistent elevation >3x ULN or signs of liver injury. Not recommended in patients with severe hepatic impairment (Child-Pugh C).
ULORIC (febuxostat) is a non-purine xanthine oxidase inhibitor indicated for chronic management of hyperuricemia in gout. Avoid use in patients with ischemic heart disease or heart failure due to increased cardiovascular events in the CARES trial. Do not use in asymptomatic hyperuricemia. Titrate from 40 mg to 80 mg if serum urate target not reached. SCr monitoring is not required, but caution with severe renal impairment (Cr Cl <30 m L/min) – no data. Avoid concomitant with azathioprine, 6-mercaptopurine, or theophylline due to XO inhibition. Coadministration with NSAIDs or colchicine is safe for flare prophylaxis. Check liver enzymes periodically as ALT elevations >3x ULN occurred in 2%.
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.,You may experience gout flares during the first few months; continue your medication and take prescribed anti-inflammatory drugs as directed.,Report any signs of heart attack or stroke (chest pain, shortness of breath, weakness on one side of body, slurred speech) immediately.,Avoid alcohol, especially beer, which can increase uric acid levels and trigger gout flares.,Inform your doctor if you are taking azathioprine, mercaptopurine, or theophylline; these are not safe to take with febuxostat.,If you have a history of heart attack, stroke, or heart disease, discuss alternative treatments with your doctor.,Seek medical attention for signs of liver injury (yellow skin/eyes, dark urine, abdominal pain, persistent nausea).,Stay hydrated to help prevent kidney stones; aim for 8-10 glasses of water daily unless otherwise advised.,Do not crush or chew tablets; swallow whole with water.
Take ULORIC once daily with or without food. Do not crush or chew tablets.,You may experience a gout flare when starting ULORIC; you will be prescribed medication (e.g., colchicine, NSAID) to prevent flares for at least 6 months.,Seek immediate medical attention if you develop chest pain, shortness of breath, rapid heartbeat, or sudden numbness/weakness – these may indicate a cardiovascular event.,Avoid drinking large amounts of alcohol or consuming high-purine foods (e.g., red meat, shellfish) as they can increase uric acid levels.,Tell your doctor if you have a history of heart disease, heart failure, stroke, or liver problems.,Report persistent nausea, right upper abdominal pain, dark urine, or yellowing of eyes/skin – signs of liver injury.
"Mercaptopurine is metabolized by xanthine oxidase. Febuxostat inhibits xanthine oxidase, leading to significantly reduced clearance of mercaptopurine and its active metabolites. This can result in severe myelosuppression, including life-threatening neutropenia and thrombocytopenia, as well as hepatotoxicity."
"The serum concentration of the active metabolites of Aminophylline can be increased when Aminophylline is used in combination with Febuxostat."
"The serum concentration of Febuxostat can be increased when it is combined with Azathioprine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FEBUXOSTAT vs ULORIC, answered by our medical review team.
FEBUXOSTAT is a Xanthine Oxidase Inhibitor that works by Febuxostat is a non-purine selective inhibitor of xanthine oxidase (XO). It inhibits both oxidized and reduced forms of XO, thereby reducing the conversion of hypoxanthine to xanthine and xanthine to uric acid, leading to decreased serum uric acid levels.. ULORIC is a Xanthine Oxidase Inhibitor that works by ULORIC (febuxostat) is a xanthine oxidase inhibitor that reduces serum uric acid levels by inhibiting the enzyme xanthine oxidase, which catalyzes the conversion of hypoxanthine to xanthine and xanthine to uric acid.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FEBUXOSTAT and ULORIC depend on the specific clinical indication. These are both Xanthine Oxidase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FEBUXOSTAT is: 40 mg orally once daily; may increase to 80 mg orally once daily if serum urate goal not achieved after 2 weeks.. The standard adult dose of ULORIC is: 40 mg orally once daily; may increase to 80 mg once daily if serum uric acid not at target after 2 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FEBUXOSTAT and ULORIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FEBUXOSTAT is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, febuxostat caused developmental toxicity (reduced fetal weight, increased skeletal variations) at ma. ULORIC is classified as Category C. Pregnancy Category C: In animal studies, febuxostat caused fetal toxicity (reduced fetal weights, increased incidence of fetal malformations) at doses equivalent to 2-4 times the h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.